FDA warns of bladder cancer with Actos

FDA is updating the label of diabetes drug Actos pioglitazone from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to warn that use of the drug for more than one year may be associated with an increased risk of bladder cancer. Takeda said in a statement it is working with FDA to update the label. The update comes less than a week after France suspended and Germany significantly restricted Actos use based on a French retrospective study showing an increased risk of bladder cancer associated with the drug. EMA's CHMP is scheduled to discuss Actos at its June 20-23 meeting (see BioCentury Extra, June 10). ...